The correlation between Cu metabolism and cell resistance to Pt drugs led to the idea that modulating the activity of Cu transporters, including ATP7A/B, might be explored to counteract drug resistance and, therefore, to improve the efficacy of platinum-based cancer therapy. Here, ATP7A is linked to cancer.